Wisconsin Alumni Research Foundation

Therapeutics & Vaccines
Therapeutics Vaccines
Treating Fibrotic Disorders by Inhibiting BMP-1-Like Proteinases
WARF: P05169US

Inventors: Daniel Greenspan, Gaoxiang Ge, Yue Zhang

The Wisconsin Alumni Research Foundation (WARF) is seeking commercial partners interested in developing a method of treating fibrotic disorders such as abnormal wound healing, surgical adhesions or deep-seated organ fibrosis.
Overview
The formation of collagen fibrils is essential to the healing of wounds and bone fractures. But excessive formation of collagenous, extracellular matrix (ECM) proteins can cause fibrotic disorders, such as keloids, surgical adhesions or organ-destroying deep-seated fibroses. Bone morphogenetic protein-1 (BMP-1) and BMP-1-like proteinases play a role in creating ECM by cleaving precursor molecules into the mature proteins needed for ECM formation.
The Invention
UW-Madison researchers have devleoped a method of treating fibrotic disorders by inhibiting BMP-1-like proteinases. The protein alpha2-macroglobulin (alpha2M), which binds peptides and particles, can be used to inhibit BMP-1-like proteinases. Each subunit of alpha2M includes sites that various proteinases can cleave, activating the alpha2M. The activated alpha2M then forms a covalent complex with the proteinase, inhibiting its proteolytic activities.

The inventors have engineered an alpha2M so that its ability to inhibit BMP-1-like proteinases is enhanced approximately 25-fold. The engineered alpha2M, or a native form, can be administered to a patient to reduce the formation of ECM. The alpha2M may be modified to further enhance its ability to inhibit BMP-1 activity.
Applications
  • Treating fibrotic disorders, such as abnormal wound healing, surgical adhesions or deep-seated organ fibrosis
Key Benefits
  • May be given to a patient following surgery to prevent excess scarring
  • Administration can be non-invasive or intravenous.
     
Additional Information
For More Information About the Inventors
For current licensing status, please contact Rafael Diaz at [javascript protected email address] or 608-960-9847

WARF